surmount-1 tirzepatide obesity nejm 2022 weight loss percent SURPASS-2 (NEJM 2021) was the definitive head-to-head: vs semaglutide 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions Novel strategies for medical management

From a patient perspective, health insurance and payer coverage guidelines surrounding rare disease treatments restrict broad access to these treatments, leaving only a small number of patients who can bypass insurance and pay for products independently

Drawing up 50 units of the 10 mg / 0.5 mL strength of Mounjaro will provide 10 mg of the tirzepatide

Food and Drug Administration (FDA) to promote blood sugar control in adult patients with type 2 diabetes when paired with a healthy lifestyle, such as dietary modifications and exercise

These agents are integral in clinical practice to improve cardiovascular outcomes in patients with diabetes

Not dramatic